The effect of PAMAM dendrimers on the antibacterial activity of antibiotics with different water solubility

Molecules

Volumn 18, Issue 7, 2013, Pages 8607-8617

  Winnicka, Katarzyna ^a   Wroblewska, Magdalena ^a   Wieczorek, Piotr ^a   Sacha, Pawel Tomasz ^a   Tryniszewska, Elzbieta Anna ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Antibacterial activity; Erythromycin; PAMAM dendrimer; Tobramycin; Water solubility

Indexed keywords

ANTIINFECTIVE AGENT; DENDRIMER; ERYTHROMYCIN; PAMAM STARBURST; TOBRAMYCIN;

ARTICLE; BACTERIUM; CHEMISTRY; DRUG EFFECT; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; SOLUBILITY; DRUG EFFECTS;

ANTI-BACTERIAL AGENTS; BACTERIA; DENDRIMERS; ERYTHROMYCIN; HUMANS; MICROBIAL SENSITIVITY TESTS; SOLUBILITY; TOBRAMYCIN;

EID: 84880780642     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules18078607     Document Type: Article

References (37)

1. European Pharmacopoeia, 6th ed.; Council of Europe: Strasbourg, France, 2007; Volume 2, pp. 1801-1803.
2. Mazzei, T.; Mini, E.; Novelli, A.A. Chemistry and mode of action of macrolides. J. Antimicrob. Chemother. 1993, 31, 1-9.
3. European Pharmacopoeia, 6th ed.; Council of Europe: Strasbourg, France, 2007; Volume 2, pp. 3085-3086.
4. Mingeot-Leclerq, M-P.; Glupczynski, Y.; Tulkens, P.M. Aminoglycosides: activity and resistance. Antimicrob. Agents Chemother. 1999, 43, 727-737.
5. Chambers, H.F.; Sande, M.A. Antimicrobial agents: The aminoglycosides. In The Pharmacological Basis of Therapeutics; Hardman, J.G., Limbrid, L.E., Molinoff, P.B., Ruddon, R.W., Goodman-Gilman, A., McGraw-Hill, Eds.; McGraw-Hill Professional: New York, NY, 1995; pp. 1103-1121.
6. Svenson, S.; Tomalia, D.A. Dendrimers in biomedical applications- Reflections on the field. Adv. Drug Deliv. Rev. 2012, 64, 102-115.
7. Caminade, A.M.; Laurent, R.; Majoral, J.P. Characterization of dendrimers. Adv. Drug Deliv. Rev. 2005, 57, 2130-2146.
8. Gillies, E.R.; Frechet, J.M. Dendrimers and dendritic polymers in drug delivery. Drug Discov. Today 2005, 10, 35-43.
9. Florence, A.T. Dendrimers: A versatile targeting platform. Adv. Drug Deliv. Rev. 2005, 57, 2104-2105.
10. Polcyn, P.; Jurczak, M.; Rajnisz, A.; Solecka, J.; Urbańczyk- Lipkowska, Z. Design of antimicrobially active small amphiphilic peptide dendrimers. Molecules 2009, 14, 3881-3905.
11. Janiszewska, J.; Sowińska, M.; Rajnisz, A.; Solecka, J.; Ła̧cka, I.; Milewski, S.; Urbańczyk-Lipkowska, Z. Novel dendrimeric lipopeptides with antifungal activity. Bioorg. Med. Chem. Lett. 2012, 22, 1388-1393.
12. Huh, A.J.; Kwon, Y.J. "Nanoantibiotics": A new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. J. Control. Release 2011, 156, 128-145.
13. Winnicka, K.; Sosnowska, K.; Wieczorek, P.; Sacha, P.T.; Tryniszewska, E. Poly(amidoamine) dendrimers increase antifungal activity of clotrimazole. Biol. Pharm. Bull. 2011, 34, 1129-1133.
14. Gardiner, J.; Freeman, S.; Leah, M.; Green, A.; Alcock, J.; D'Emanuele, A. PAMAM dendrimers for the delivery of the antibacterial Triclosan. J. Enzyme Inhib. Med. Chem. 2008, 23, 623-628.
15. Roseita, E.; Tomalia, D.A. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov. Today 2001, 6, 427-436.
16. Winnicka, K.; Bielawski, K.; Rusak, M.; Bielawska, A. The effect of generation 2 and 3 poly(amidoamine) dendrimers on viability of human breast cancer cells. J. Health. Sci. 2009, 55, 169-177.
17. Cheng, Y.; Xu, Z.; Ma, M.; Xu, T. Dendrimers as drug carriers: Applications in different routes of drug administration. J. Pharm. Sci. 2008, 97, 123-143.
18. Cheng, Y.; Qu, H.; Ma, M.; Xu, Z.; Xu, P.; Fang, Y.; Xu, T.; Wen, L. Polyamidoamine (PAMAM) dendrimers as biocompatible carriers of quinolone antimicrobials: An in vitro study. Europ. J. Med. Chem. 2007, 42, 1032-1038.
19. Ma, M.; Cheng, Y.; Xu, Z.; Xu, P.; Qu, H.; Fang, Y.; Xu, T.; Wen, L. Evaluation of polyamidoamine (PAMAM) dendrimers as drug carriers of anti-bacterial drugs using sulfamethoxazole (SMZ) as model drug. Eur. J. Med. Chem. 2007, 42, 93-98.
20. Charles, S.; Vasanthan, N.; Kwon, D.; Sekosan, G.; Ghosh, S. Surface modification of poly(amidoamine) (PAMAM) dendrimer as antimicrobial agents. Tetrahedron Lett. 2012, 53, 6670-6675.
21. Strydom, S.J.; Rose, W.E.; Otto, D.P.; Liebenberg, W.; de Villiers, M.M. Poly(amidoamine) dendrimer-mediated synthesis and stabilization of silver sulfonamide nanoparticles with increased antibacterial activity. Nanomed. Nanotechnol. Biol. Med. 2013, 9, 85-93.
22. McNerny, D.Q.; Leroueil, P.R.; Baker, J.R. Understanding specific and nonspecific toxicities: A requirement for the development of dendrimer-based pharmaceuticals. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2010, 2, 249-259.
23. Lopez, A.I.; Reins, R.Y.; McDermott, A.M.; Trautner, B.W.; Cai, C. Antibacterial activity and cytotoxicity of PEGylated poly(amidoamine) dendrimers. Mol. Biosyst. 2009, 5, 1148-1156.
24. Ortega, P.; Copa-Patino, J.L.; Munoz-Fernandez, M.A.; Soliveri, J.; Gomez, R.; Mata, F.J. Amine and ammonium functionalization of chloromethylsilane-ended dendrimers. Antimicrobial activity studies. Org. Biomol. Chem. 2008, 6, 3264-3269.
25. Balogh, L.; Swanson, D.R.; Tomalia, D.A.; Hagnauer, G.L.; McManus, A.T. Dendrimer-Silver complexes and nanocomposites as antimicrobial agents. Nano. Lett. 2001, 1, 18-21.
26. Winnicka, K.; Wroblewska, M.; Wieczorek, P.; Sacha, P.T.; Tryniszewska, E. Hydrogel of ketoconazole and PAMAM dendrimers: formulation and antifungal activity. Molecules 2012, 17, 4612-4624.
27. Hong, S.; Bielinska, A.U.; Mecke, A.; Keszler, B.; Beals, J.; Shi, X.; Balogh, L.; Orr, B.G.; Baker, J.R., Jr.; Banaszak Holl, M.M. Interactions of poly(amidoamine) dendrimers with supported lipid bilayer and cells: hole formation and the relation to transport. Bioconjugat. Chem. 2004, 15, 774-782.
28. Chen, C.Z.; Cooper, S.L. Interactions between dendrimer biocides and bacterial membranes. Biomaterials 2002, 23, 3359-3368.
29. Sayed, M.E.; Ginski, M.; Rhodes, H. Transepithelial transport of polyamidoamine dendrimers across Caco-2 cell monolayers. J. Control. Release 2002, 81, 355-365.
30. Xue, X.; Chen, X.; Mao, X.; Hou, Z.; Zhou, Y.; Bai, H.; Meng, J.; Da, F.; Sang, G.; Wang, Y.; Luo, X. Amino-terminated generation 2 poly(amidoamine) dendrimer as a potential broad-spectrum, nonresistance-inducing antibacterial agent. AAPS J. 2013, 15, 132-142.
31. Calabretta, M.K.; Kumar, A.; McDermott, A.M.; Cai, C. Antibacterial activities of poly(amidoamine) dendrimers terminated with amino and poly(ethylene glycol) groups. Biomacromolecules 2007, 8, 1807-1811.
32. Wang, B.; Navath, R.S.; Menjoge, A.R.; Balakrishnan, B.; Bellair, R.; Dai, H.; Romero, R.; Kannan, S.; Kannan, R.M. Inhibition of bacterial growth and intramniotic infection in a guinea pig model of chorioamnionitis using PAMAM dendrimers. Int. J. Pharm. 2010, 395, 298-308.
33. Scott, J.R.; Barnett, T.C. Surface proteins of gram-positive bacteria and how they get there. Annu. Rev. Microbiol. 2006, 60, 397-423.
34. Cabeen, M.T.; Jacobs-Wagner, C.: Bacterial cell shape. Nat. Rev. Microbiol. 2005, 3, 601-610.
35. Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by broth dilution. In Processing of European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), EUCAST Discussion Document E.Dis 5.1, 2003.
36. Kamarei, F.; Movaghari, F.; Ghaffari, A.; Bozchalooi, I.S.; Zamani, A.; Jabbari, A. Development of stability-indicating high performance liquid chromathography method for assay of erythromycin ethylosuccinate in powder for oral suspension dosage form. Arab. J. Chem. 2011, 30, 1-7.
37. Kanfer, I.; Skinner, M.F.; Walker, R.B. Analysis of macrolide antibiotics. J. Chromatogr. A 1998, 812, 255-286.